Doctor of Philosophy in Pharmaceutical Sciences (PhD)
Developing selective small-molecule probes for STAT3 using thermal stability assays
If you are passionate about health sciences research that makes a difference in people's lives, you're in good hands. We offer award-wining graduate programs led by world-class researchers. You'll have access to top-tier facilities and be working alongside the best and brightest in the field, conducting research that addresses real life problems. Our paradigm-changing approach is collaborative, innovative, and results-driven.
We're tackling diseases like asthma / chronic obstructive pulmonary disease, diabetes, cancer, heart disease, and arthritis. We're developing better ways to deliver drugs and prevent adverse drug reactions. And we're conducting clinical and economic research in pharmaceutical outcomes.
Our reputation as a top research centre attracts some of the brightest and most productive minds in the field. Our faculty includes Canada Research Chairs, Michael Smith Foundation for Health Research Scholars and Senior Scholars, and Distinguished University Scholars.
We are innovators in pharmacy education, research and practice, with the goal of supporting the optimization of drug therapy in the pursuit of improved patient outcomes.
adMare BioInnovations is located in our building. It is an independent, non-profit organization with a focus on bridging the gap between academic discoveries in the health sciences and the development of new medicines to treat human disease. The Faculty partners with adMare BioInnovations to provide unique research and mentoring opportunities for MSc and PhD students.
We are also home to several sophisticated research centres that specialize in the areas of human genome and exome sequencing, and health outcomes research.
Opened in 2012, the Pharmaceutical Sciences Building at UBC is a state-of-the-art learning and research facility. The building houses modern, modular labs designed specifically for the type of research intended for the space. Our classroom facilities are fitted with advanced technology to facilitate new modes of learning.
Measuring 246,000 square feet, it's an eye-catching addition to our campus, and has drawn attention and admiration from around the world—including 15 awards of excellence.
As a leading research faculty, we conduct ground-breaking research in the pharmaceutical sciences – all with the goal of addressing the pressing health needs of society and improving lives. Our research activities centre around four areas of focus.
This theme covers our activities in epidemiological analysis, health outcomes and health economics research seeking solutions for the predictive enhancement of intervention strategies for practical and preventive healthcare. The impact of this work is used to shape policy to optimize the allocation of health care resources as well as defining the efficacy of healthcare interventions and strategy.
This highly interdisciplinary theme embodies research directed at the interactions of therapeutic agents with human cells, and covers fundamental questions of the mechanisms of the drug action through to the behaviour of drugs in human systems. These studies are used to inform and optimize the development and delivery of drug intervention regimes for clinical practice and the pharmaceutical industry.
This theme applies our expertise in the chemical biology of the fabrication and handling of nanoscopic materials to drug discovery and delivery. Sensing and screening technologies are also an important focus.
Our research in this theme addresses the issue of scholarship in pharmacy and the pharmaceutical sciences with a view to augment our educational research capacity and enhance the methodologies of teaching practice, student learning and curriculum decision-making.
|Burt, Helen Mary||Nanotechnology, non-sized drug carriers, nanoparticulte drug delivery|
|Cairns, Brian||Neurosciences, biological and chemical aspects; Neurosciences, medical and physiological and health aspects; Pharmacology and pharmaceutical sciences (except clinical aspects); electrophysiology; headache; Neuropharmacology; Oro-Facial Pain; pain; pain mechanisms; peripheral analgesics; sex-related differences; temporomandibular disorders|
|Chang, Thomas||Pharmacology and pharmaceutical sciences (except clinical aspects); Drug Metabolism; Cytochrome P450; Drug-Metabolizing Enzymes; Gene Expression; Gene regulation; Nuclear Receptor; Pharmacology|
|Collier, Abby||Drugs in children, Drugs in pregnancy, Developmental pharmacology, Drug metabolism, Pharmacokinetics, Drug metabolism and pharmacokinetics, primarily of the phase II (conjugation) enzymes, focused on pregnancy and pediatrics|
|Conklin, Annalijn||Human nutrition and dietetics; Pharmacology and pharmaceutical sciences (except clinical aspects); Chronic Diseases in Elderly; Community Health / Public Health; disease management evaluation; food and nutrition policy; Gender Epidemiology; gender and health equity; Health Policies; healthcare quality improvement; healthy ageing; Indigenous health; Obesity; obesity & CVD risk factors; Professional Practices; Social Determinants of Dietary and Metabolic Disorders; social nutritional epidemiology|
|Coughtrie, Michael||Drug metabolizing enzymes|
|Cragg, Jacquelyn||Epidemiology (except nutritional and veterinary epidemiology); data science; open science; Causal inference; Drug Effectiveness; Drug Safety; Epidemiology; neuro-epidemiology; Neurological diseases; Spinal cord injury; Amyotrophic Lateral Sclerosis (ALS); multiple sclerosis; Parkinson’s disease|
|De Vera, Mary||examining how eHealth technologies can support new and existing models of care to improve care delivery and patient outcomes; exploring patients' perspectives and experiences with medication taking and adherence; and evaluating the use and impacts of medications among pregnant women, particularly with inflammatory conditions.|
|Frankel, Adam||Pharmacology and pharmaceutical sciences (except clinical aspects); Biological and Biochemical Mechanisms; Bioactive Molecules; Organic Molecules and Biomolecules; Proteins; arginine methylation; autophagy; Chemical Biology; drug discovery; post-translational modifications; Protein Biochemistry; yeast|
|Giaever, Guri||Model organisms, human therapeutics, high-throughput cell biology, drug synergy, technologies for understanding relationship between chromatic structure and transcriptional regulation|
|Hafeli, Urs||Pharmacokinetics; Imaging; Radiotherapy; Immunotherapy; Development of Drug Delivery Systems; Radiopharmaceuticals; Radioimmunotherapy; Magnetic Targeting; Targeted Drug Delivery; Novel polymers; Nanoparticles; Microspheres; Microneedles; Bioconjugates|
|Harrison, Mark||measurement and valuation of health, health technology and policy assessment, and preferences for healthcare interventions; evaluation/re-evaluation of the type of health care that is provided, the point in the treatment pathway, and the way in which it is delivered|
|Hedtrich, Sarah||Pharmacology and pharmaceutical sciences (except clinical aspects); Nanotechnologies; Structural Tissue Engineering / Biomaterials; Inflammatory Respiratory Diseases; Skin; New Biomedical Approaches - Alternatives to Animal Testing; Novel therapies for inflammatory and genetic diseases of human epithelia; Tissue Regeneration and Wound Healing; Topical drug delivery and Nanomedicine|
|Jarvis-Selinger, Sandra||Education, human learning, development, and instruction, education innovation, konwledge translation, teaching excellence, curriculum design, technology|
|Kumar, Ujendra||Somatostatin hormone, molecular pharmacology, Somatostatin, , Hormones, somatostatin, locomotor and cognitive function, neurodegenerative diseases, drugs|
|Lalji, Fawziah||Pharmacology and pharmaceutical sciences (except clinical aspects); Pharmacoepidemiology; Infectious diseases; Vaccination; Antibiotics and Resistance; Tuberculosis|
|Li, Shyh-Dar||Pharmacology and pharmaceutical sciences (except clinical aspects); biopharmaceutics; drug delivery; nanomedicine; pharmaceutics|
|Loewen, Peter||Pharmacology and pharmaceutical sciences (except clinical aspects); Cardiovascular diseases; Arrhythmia; Thrombosis and Embolism; Heart Failure; Pharmacoepidemiology; stroke; Health Care Technologies; Professional Practices; Hematology; decision making; adherence to medication; atrial fibrillation; clinical prediction rules; healthcare communication technologies; hospital pharmacy practice; knowledge translation of evidence to patient care; patient complexiometry; patient decision aids; patient education; pharmacy practice; prediction of stroke and bleeding in atrial fibrillation patients; quality of care, quality drug therapy; Shared decision-making; stroke prevention therapy; use of mobile technology for clinical decision-making|
|Lynd, Larry||health economics, orphan drugs, pharmaceutical policy, respiratory medicine, epidemiology, pharmacoepidemiology, rare diseases|
|Maharaj, Anil||Pharmacology and pharmaceutical sciences, n.e.c.; Pharmacometrics; Pharmacokinetics/Pharmacodynamics; Obstetric and Pediatric Pharmacology|
|McCormack, James||Knowledge translation and evidence-based practice|
|Nislow, Corey||genomics and develops biotechnology tools to address both fundamental and applied biological questions; Parallel genome-wide chemical genomic screens; High throughput cell-based screens; Next Generation Sequencing|
|Page, Brent||Pharmacology and pharmaceutical sciences (except clinical aspects); Cell Signaling and Cancer; Cancer; Cell signaling; Chemical Biology; Drug development; drug discovery; Medicinal Chemistry; Target Engagement|
|Rodrigues, Brian||Pharmacology and pharmaceutical sciences (except clinical aspects); Diabetes; Cardiomyopathy; Heart Failure; Energy Metabolism; Cardiovascular metabolism; Endothelial cell - cardiomyocyte crosstalk; Vascular Endothelial Growth factors|
This is an incomplete sample of recent publications in chronological order by UBC faculty members with a primary appointment in the Faculty of Pharmaceutical Sciences.
|2020||Dr. Lin performed structure-activity relationship studies on anti-HIV molecules. During this process, she discovered novel chemical reactivities of these compounds. The findings are crucial for the future development of biologically active molecules toward treatments of various diseases and crop protection.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2020||Dr. Agnoletti investigated the use of polymeric microspheres as carriers to deliver antibiotics selectively to the lungs after intravenous administration. Her findings support the passive lung targeting strategy to improve the treatments of bacterial lung infections and, potentially, other lung diseases.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2020||Dr. Lal studied the role of the protein VEGFB in the diabetic heart. He found that this growth factor has the potential to protect against the changes that occur in the heart following diabetes and can lead to heart failure. This research helps in identifying a novel therapeutic target to prevent diabetic heart disease.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2020||Dr. Atiquzzaman revealed the mediating role of NSAIDs in the increased risk of heart diseases among osteoarthritis patients. He also evaluated the cardiovascular safety of various NSAIDs used to treat osteoarthritis. This will help to understand the link between osteoarthritis and heart disease better and improve the safe treatment of this disease.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2020||Dr. Johnson evaluated strategies for improving the diagnosis of chronic obstructive pulmonary disease (COPD). She found that early detection strategies for COPD are cost-effective, and that the risk of COPD should be assessed regularly at primary care visits. Her research can help to reduce the burden of COPD on patients and the healthcare system.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2019||Current HIV treatment can effectively manage infection, but it is not a cure. Hence, there is a need for new kinds of anti-HIV drugs. Dr. Zamiri discovered two anti-HIV molecules active in both wild and drug resistant HIV strains. Her research suggests a mechanism of action different from the current HIV drugs and may inform future therapies.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2019||Dr. Gorrin constructed a model based on his conversations with people with asthma and measured how participants in two asthma studies reported their medication usage. The integration of his findings helped to understand why some people don't take the medication and how to encourage regular medication usage.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2019||Drug discovery can be lengthy, complicated and requires extensive resources. Working in partnership with the pharmacy and chemistry departments, Dr. Koperniku explored access to pharmaceutically relevant small molecules. Her work advances the optimization of pharmaceuticals and informs improved patient care. Her past and future dedication is to serve humanity.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2019||Dr. Wang found out that heparanase, using its properties to promote cell survival, protect the heart cells against multiple stresses frequently seen in patients with ischemia and diabetes-induced heart diseases, in both cell experiments and animal studies. This research could help devise new strategies to combat heart diseases.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|
|2019||Dr. Lambert investigated causes of pain in fibromyalgia and determined that specialized immune cells in the brain may play a critical role. She also created two novel molecules which act on the endocannabinoid system to reduce the pain-causing actions of these immune cells. Her work may form the basis of a new therapeutic strategy for chronic pain.||Doctor of Philosophy in Pharmaceutical Sciences (PhD)|